P650: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐5948, AN ORAL BTK DEGRADER, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES.
| Autor: | Linton, K., Collins, G. P., El‐Sharkawi, D., Mous, R., Forconi, F., Tan, M., Nandakumar, S., Meredith, E., Jameson, K. L., Injac, S. G., Doorduijn, J. |
|---|---|
| Zdroj: | HemaSphere; 2022 Supplement 3, Vol. 6, p548-549, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Plný text